UHPLC-MS/MS-based untargeted lipidomics analysis of septic patients

Liang, Jifang; Li, Jing; Zhang, Junkun; Rong, Jianrong; Wang, Xiuzhe; Zhao, Cheng; Zhang, Hailong; Shi, Hongbo; Wu, Weidong

doi:10.1016/j.cca.2023.117336

Cited by 2 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sixty-four lipid levels from 65 identified molecules were decreased in septic patients, while the level of PE (34:2) was increased compared to that in control group patients. All major PCs were decreased [ 63 ].…”

Section: Resultsmentioning

confidence: 99%

“…Moreover, lipid profile helps to monitor the administration of clinical treatment and diagnose human diseases [ 59 ]. Recently, lipid changes have often been evaluated in septic patients [ 60 , 61 , 62 , 63 ]. It was demonstrated that sepsis is usually associated with the downregulation of lysophosphatidylcholine (LPC) levels, increased plasma free fatty acid (FA) and ceramide (Cer) species levels, or changes in the metabolism of polyunsaturated FAs (PUFA) in plasma [ 64 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Implementation of Modern Therapeutic Drug Monitoring and Lipidomics Approaches in Clinical Practice: A Case Study with Colistin Treatment

Gerhardtova,

Cizmarova,

Jankech

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Nowadays, lipidomics plays a crucial role in the investigation of novel biomarkers of various diseases. Its implementation into the field of clinical analysis led to the identification of specific lipids and/or significant changes in their plasma levels in patients suffering from cancer, Alzheimer’s disease, sepsis, and many other diseases and pathological conditions. Profiling of lipids and determination of their plasma concentrations could also be helpful in the case of drug therapy management, especially in combination with therapeutic drug monitoring (TDM). Here, for the first time, a combined approach based on the TDM of colistin, a last-resort antibiotic, and lipidomic profiling is presented in a case study of a critically ill male patient suffering from Pseudomonas aeruginosa-induced pneumonia. Implementation of innovative analytical approaches for TDM (online combination of capillary electrophoresis with tandem mass spectrometry, CZE-MS/MS) and lipidomics (liquid chromatography–tandem mass spectrometry, LC-MS/MS) was demonstrated. The CZE-MS/MS strategy confirmed the chosen colistin drug dosing regimen, leading to stable colistin concentrations in plasma samples. The determined colistin concentrations in plasma samples reached the required minimal inhibitory concentration of 1 μg/mL. The complex lipidomics approach led to monitoring 545 lipids in collected patient plasma samples during and after the therapy. Some changes in specific individual lipids were in good agreement with previous lipidomics studies dealing with sepsis. The presented case study represents a good starting point for identifying particular individual lipids that could correlate with antimicrobial and inflammation therapeutic management.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Implementation of Modern Therapeutic Drug Monitoring and Lipidomics Approaches in Clinical Practice: A Case Study with Colistin Treatment

Gerhardtova,

Cizmarova,

Jankech

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…An altered metabolism of PCs has been reported to be associated with sepsis [ 74 ]. There is evidence of both increased and reduced concentrations of PC species in the blood.…”

Section: Research Field Landscapementioning

confidence: 99%

“…The detection and quantification of glycerophospholipids are mostly implemented by LC modifications with MS: UHPLC-MS/MS [ 74 ], UPLC-Q-TOF-MS [ 83 ], and UPLC coupled to ESI-QTOF [ 79 ]. For large clinical studies of glycerophospholipids, an accurate and fast method with application to different biological samples is needed.…”

Section: Research Field Landscapementioning

confidence: 99%

“…Circulating histones in plasma and specific lipid classes, such as cholesterol esters and oxidized phospholipids in high-density lipoprotein, are relevant markers for predicting sepsis prognosis [ 170 , 171 , 172 ]. Among other predictive biomarkers from lipid classes are PC and LPC [ 74 ]; these lipids were selected as potential biomarkers in studies exploring sepsis progression [ 75 , 173 ]. Distinct metabolic alterations become evident at various stages of sepsis progression, providing crucial insights into its dynamic nature.…”

Section: Disease Study Landscapementioning

confidence: 99%

See 1 more Smart Citation

Advances in Mass Spectrometry-Based Blood Metabolomics Profiling for Non-Cancer Diseases: A Comprehensive Review

Demicheva,

Dordiuk,

Polanco Espino

et al. 2024

Metabolites

View full text Add to dashboard Cite

Blood metabolomics profiling using mass spectrometry has emerged as a powerful approach for investigating non-cancer diseases and understanding their underlying metabolic alterations. Blood, as a readily accessible physiological fluid, contains a diverse repertoire of metabolites derived from various physiological systems. Mass spectrometry offers a universal and precise analytical platform for the comprehensive analysis of blood metabolites, encompassing proteins, lipids, peptides, glycans, and immunoglobulins. In this comprehensive review, we present an overview of the research landscape in mass spectrometry-based blood metabolomics profiling. While the field of metabolomics research is primarily focused on cancer, this review specifically highlights studies related to non-cancer diseases, aiming to bring attention to valuable research that often remains overshadowed. Employing natural language processing methods, we processed 507 articles to provide insights into the application of metabolomic studies for specific diseases and physiological systems. The review encompasses a wide range of non-cancer diseases, with emphasis on cardiovascular disease, reproductive disease, diabetes, inflammation, and immunodeficiency states. By analyzing blood samples, researchers gain valuable insights into the metabolic perturbations associated with these diseases, potentially leading to the identification of novel biomarkers and the development of personalized therapeutic approaches. Furthermore, we provide a comprehensive overview of various mass spectrometry approaches utilized in blood metabolomics research, including GC-MS, LC-MS, and others discussing their advantages and limitations. To enhance the scope, we propose including recent review articles supporting the applicability of GC×GC-MS for metabolomics-based studies. This addition will contribute to a more exhaustive understanding of the available analytical techniques. The Integration of mass spectrometry-based blood profiling into clinical practice holds promise for improving disease diagnosis, treatment monitoring, and patient outcomes. By unraveling the complex metabolic alterations associated with non-cancer diseases, researchers and healthcare professionals can pave the way for precision medicine and personalized therapeutic interventions. Continuous advancements in mass spectrometry technology and data analysis methods will further enhance the potential of blood metabolomics profiling in non-cancer diseases, facilitating its translation from the laboratory to routine clinical application.

show abstract

UHPLC-MS/MS-based untargeted lipidomics analysis of septic patients

Cited by 2 publications

References 23 publications

Implementation of Modern Therapeutic Drug Monitoring and Lipidomics Approaches in Clinical Practice: A Case Study with Colistin Treatment

Implementation of Modern Therapeutic Drug Monitoring and Lipidomics Approaches in Clinical Practice: A Case Study with Colistin Treatment

Advances in Mass Spectrometry-Based Blood Metabolomics Profiling for Non-Cancer Diseases: A Comprehensive Review

Contact Info

Product

Resources

About